ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0046

Socioeconomic Disparities in Functional Status Among RA Patients: A Longitudinal Analysis Using RISE Data

Jing Li1, Gabriela Schmajuk2, Michael Evans3, Zara Izadi4, Patricia Katz5, Alexis Ogdie6, Lisa Suter7 and Jinoos Yazdany3, 1University of California, San Francisco, San Francisco, CA, 2University of California, San Francisco, Atherton, CA, 3Ucsf, San Francisco, CA, 4University of California San Francisco, San Francisco, CA, 5University of California, San Francisco, Novato, CA, 6Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 7Yale School of Medicine, New Haven, CT

Meeting: ACR Convergence 2020

Keywords: Disparities, functional status, Health Care, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Healthcare Disparities in Rheumatology Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Prior studies have shown that RA outcomes, including disease activity, erosions, and disability, are worse among patients with low socioeconomic status (SES). However, few studies have examined the relationship between RA functional outcomes and SES at the national level. We used the ACR’s Rheumatology Informatics System for Effectiveness (RISE) registry to investigate the relationship between individual SES and functional status (FS) among individuals with RA across U.S. rheumatology practices.

Methods: Data derived from RISE, a national EHR-enabled registry that passively collects data on all patients seen by participating rheumatology practices. As of 2018, RISE held validated data from 1,113 providers in 226 practices, representing about 32% of the U.S. clinical rheumatology workforce. Patients included in this study were ≥18 years old, had ≥ 2 visits with RA codes ≥ 30 days apart, and ≥ 1 FS measure (MDHAQ, HAQII, or HAQ) in 2016-2018. As a proxy for SES, we used the Area Deprivation Index (ADI) score, a 9-digit ZIP-code-based indicator of neighborhood socioeconomic disadvantage (range 1-100, higher score = lower SES).  

We investigated cross-sectional and longitudinal relationships between FS and SES. In a cross-sectional analysis, we calculated the mean FS scores for each quintile of SES. We used only the most recent FS measure for patients with ≥ 1 score recorded during a calendar year. In a longitudinal analysis, patients with ≥2 of the same FS measure, at least 12 months apart, were categorized as worsening (Y/N) based on the minimal clinically important difference for each tool. We used multi-level logistic regression to assess the association of worsening FS for each quintile of SES, accounting for age, sex, race, baseline FS score, and clustering by practice.

Results: 83,965 patients from 109 practices were included (characteristics in Table). MDHAQ was the most commonly reported FS measure (67.8% of patients), followed by HAQ (24.4%) and HAQII (7.8%). Overall, mean (SD) FS scores for these measures were 2.1 (2.0), 0.89 (0.58), 0.9 (0.6), respectively.

In the cross-sectional analysis, mean FS score was worse at lower SES levels, regardless of the measure used (p-trend< 0.05, see Figure). Among 24,846 RA patients included in the longitudinal analysis with MDHAQ scores, the proportion of patients with a worsening score increased modestly as lower SES levels, even after adjustment (p< 0.05): in the highest SES quintile, 12.7% (95% CI 8.9%-16.5%) patients worsened; in the lowest SES quintile, 16.6% (95% CI 12.1%-21.1%) worsened. The same trend was observed for patients with HAQ and HAQII.

Conclusion: We found evidence of significant disparities in FS across SES in this national cohort of individuals with RA, with worse functional status across each successive lower quintile of SES. In addition, FS declined more rapidly over time in those with lower SES. Future research is needed to identify the source of these disparities, which exist in spite of access to rheumatologic care for all patients in the cohort.

Disclaimer: This data was supported by the ACR’s RISE Registry. However, the views expressed represent those of the authors, not necessarily those of the ACR.


Disclosure: J. Li, None; G. Schmajuk, None; M. Evans, None; Z. Izadi, None; P. Katz, None; A. Ogdie, AbbVie, 5, Amgen, 2, 5, BMS, 1, Celgene, 1, Corrona, 1, Janssen, 1, Eli Lilly, 1, Novartis, 2, 5, Pfizer, 2, 5, National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2, Rheumatology Research Foundation, 2, National Psoriasis Foundation, 2; L. Suter, None; J. Yazdany, Eli Lilly, 5, Astra Zeneca, 5.

To cite this abstract in AMA style:

Li J, Schmajuk G, Evans M, Izadi Z, Katz P, Ogdie A, Suter L, Yazdany J. Socioeconomic Disparities in Functional Status Among RA Patients: A Longitudinal Analysis Using RISE Data [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/socioeconomic-disparities-in-functional-status-among-ra-patients-a-longitudinal-analysis-using-rise-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/socioeconomic-disparities-in-functional-status-among-ra-patients-a-longitudinal-analysis-using-rise-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology